Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional) - PAR-25-328
Funder
National Institutes of Health
LOI Deadline
LOI Required
Recommended, but not required
Application Deadline
Maximum Project Duration
3 years
Research Focus Areas
Pharmacotherapy
Pharmacology
Substance Use/Misuse/Addiction
Research Methods
Randomized Control Trials (RCT)
Description
The purpose of this funding opportunity is to support research to advance the development of safe and effective medications for the treatment of Substance Use Disorders (SUD). It includes preclinical and/or clinical research projects, from lead optimization all the way Phase I, Phase II, and Phase III clinical trials. The goal is to fund studies that will have high impact and quickly yield the necessary results to advance medications closer to FDA approval.